WE CLAIM:

1. A solid dosage form comprising:

bupropion hydrochloride; and

a stabilizer, wherein the stabilizer comprises glucono delta lactone or its corresponding open chain hydroxy acid derivative.

2. The solid dosage form of claim 1, wherein the bupropion hydrochloride retains at least 80% of the bupropion hydrochloride potency after storage for three months at 40°C and 75% relative humidity.

3. The solid dosage form of claim 1, wherein the stabilizer is glucono delta lactone.

4. The solid dosage form of claim 1, wherein the stabilizer is a corresponding open chain hydroxy acid derivative of glucono delta lactone.

5. The solid dosage form of claim 4, wherein the corresponding open chain hydroxy acid derivative of glucono delta lactone is gluconic acid.

6. The solid dosage form of claim 1, wherein the concentration of glucono delta lactone or corresponding open chain hydroxy derivative comprises from about 5% to about 100% by weight of the bupropion hydrochloride.

7. The solid dosage form of claim 1, wherein the concentration of glucono delta lactone or corresponding open chain hydroxy derivative comprises from about 5% to about 50% by weight of the bupropion hydrochloride.

8. The solid dosage form of claim 1, wherein the amount of bupropion hydrochloride comprises between about 25 and about 500 mg w/w of the solid dosage form.

9. The solid dosage form of claim 1, wherein the solid dosage form comprises one or more of a tablet, a capsule, and a granulate with or without an immediate release profile, a modified release profile, or an extended release profile.

10. The solid dosage form of claim 9, wherein the solid dosage form comprises a tablet.

11. The solid dosage form of claim 10, wherein the tablet comprises a sustained release tablet.

12. The solid dosage form of claim 9, wherein the solid dosage form comprises a capsule.

13. The solid dosage form of claim 12, wherein the capsule comprises a sustained release capsule.

14. The solid dosage form of claim 1, further comprising one or more pharmaceutically acceptable excipients comprising one or more of rate controlling polymers, diluents, binders, disintegrants, lubricants, glidants, and coloring agents.

15. The solid dosage form of claim 14, wherein the release rate controlling polymers comprises one or more of cellulose derivatives, acrylates, a mixture of polyvinlyacetate and povidone, polyethylene oxides, starch and its derivatives, gums, alginates, carbohydrate based polymers, and polysaccharide.

16. The solid dosage form of claim 14, wherein the cellulose derivative comprises one or more of ethyl cellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, and sodium carboxymethylcellulose.

17. The solid dosage form of claim 16, wherein the cellulose derivative comprises hydroxypropyl cellulose.

18. The solid dosage form of claim 14, wherein the diluent comprises microcrystalline cellulose.

19. The solid dosage form of claim 14, wherein the lubricant comprises stearic acid.

20. A process for preparing a solid dosage form of bupropion hydrochloride, the process comprising;

mixing bupropion hydrochloride and a stabilizer to form a blend, wherein the stabilizer comprises glucono delta lactone or its corresponding open chain hydroxy acid derivative; and

forming the blend into a solid dosage form.

21. The process of claim 20, wherein the solid dosage form retains at least 80% of the bupropion hydrochloride potency after storage for three months at 40°C and 75% relative humidity.

22. The process of claim 20, wherein the stabilizer is glucono delta lactone.

23. The process of claim 20, wherein the stabilizer is a corresponding open chain hydroxy acid derivative of glucono delta lactone.

24. The process of claim 23, wherein the corresponding open chain hydroxy acid derivative of glucono delta lactone is gluconic acid.

25. The process of claim 20, wherein the concentration of glucono delta lactone or corresponding open chain hydroxy derivative comprises from between about 5% to about 100% by weight of bupropion hydrochloride.

26. The process of claim 25, wherein the concentration of glucono delta lactone or corresponding open chain hydroxy derivative comprises from between about 5% to about 50% by weight of bupropion hydrochloride.

27. The process of claim 20, wherein the amount of bupropion hydrochloride comprises from between about 25 to about 500 mg w/w of the solid dosage form.

28. The process of claim 20, wherein forming the blend into a solid dosage form comprises forming a tablet, capsule or granulate with or without an immediate release profile, a modified release profile, or an extended release profile.

29. The process of claim 28, wherein the solid dosage form comprises a tablet.

30. The process of claim 29, wherein the tablet comprises a sustained release tablet.

31. The process of claim 28, wherein the solid dosage form comprises a capsule.

32. The process of claim 31, wherein the capsule comprises a sustained release capsule.

33. The process of claim 20, wherein the mixing comprises wet granulation.

34. The process of claim 20, wherein the mixing comprises dry granulation.

35. The process of claim 20, wherein the mixing comprises direct compression.

36. The process of claim 20, wherein the solid dosage form further comprises one or more pharmaceutically acceptable excipients selected from rate controlling polymers, diluents, binders, disintegrants, lubricants, glidants and coloring agents.

37. The process of claim 36, wherein the release rate controlling polymer comprises one or more of cellulose derivatives, acrylates, a mixture of polyvinlyacetate and povidone, polyethylene oxides, starch and their derivatives, gums, alginates, carbohydrate based polymers, and polysaccharide.

38. The process of claim 37, wherein the cellulose derivative comprises one or more of ethyl cellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, and sodium carboxymethylcellulose.

39. The process of claim 38, wherein the cellulose derivative comprises hydroxypropyl cellulose.

40. The process of claim 36, wherein the diluent comprises microcrystalline cellulose.

41. The process of claim 36, wherein the lubricant comprises stearic acid.

42. A method of treating either or both of depression and nicotine addiction in a human, the method comprising orally administering to a human in need thereof a solid dosage form comprising bupropion hydrochloride and a stabilizer, wherein the stabilizer comprises glucono delta lactone or its corresponding open chain hydroxy acid derivative.

43. The method of claim 42, wherein the bupropion hydrochloride retains at least 80% of the bupropion hydrochloride potency after storage for three months at 40°C and 75% relative humidity.

44. The method of claim 42, wherein the stabilizer is glucono delta lactone.

45. The method of claim 42, wherein the stabilizer is a corresponding open chain hydroxy acid derivative of glucono delta lactone.

46. The method of claim 45, wherein the corresponding open chain hydroxy acid derivative of glucono delta lactone is gluconic acid.

47. The method of claim 42, wherein the concentration of glucono delta lactone or corresponding open chain hydroxy derivative comprises from about 5% to about 100% by weight of the bupropion hydrochloride.

48. The method of claim 42, wherein the concentration of glucono delta lactone or corresponding open chain hydroxy derivative comprises from about 5% to about 50% by weight of the bupropion hydrochloride.

49. The method of claim 42, wherein the amount of bupropion hydrochloride comprises between about 25 and about 500 mg w/w of the solid dosage form.

50. The method of claim 42, wherein the solid dosage form comprises one or more of a tablet, a capsule, and a granulate with or without an immediate release profile, a modified release profile, or an extended release profile.